A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia

What's the purpose of this trial?

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* Newly diagnosed:

* Therapy-related acute myeloid leukemia (AML)
* AML with antecedent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
* AML with MDS-related changes (as per World Health Organization \[WHO\])
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
* Plasma creatinine =\< 1.5 x upper limit of normal (ULN)
* Total bilirubin \< 2.0 mg/dL
* Serum alanine aminotransferase and aspartate aminotransferase \< 3 x ULN
* Left ventricular ejection fraction by echocardiogram or multiple-gated acquisition \>= 50%
* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment and commit to two forms of birth control
* Men must use a latex condom during any sexual contact with women of childbearing potential
* Willing to adhere to protocol specific requirements
* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

* Prior treatment of AML
* Known clinically active central nervous system (CNS) leukemia
* Core-binding factor leukemia
* Acute promyelocytic leukemia
* Uncontrolled other malignancy
* Prior anthracycline exposure \> 368 mg/m\^2 of daunorubicin or equivalent
* Cardiovascular disease resulting in heart failure (New York Heart Association class III or IV), unstable angina (angina symptoms at rest), or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
* Hypersensitivity to cytarabine, daunorubicin, or liposomal drugs
* Known active HIV infection
* Known history of active hepatitis B or C infection
* Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)
* Evidence of ongoing, uncontrolled systemic infection
* Pregnant or breastfeeding women
* Subject with concurrent severe and/or uncontrolled medical or psychiatric conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy
* History of Wilson disease or other copper-handling disorders
* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Additional Trial Information

Phase 2

Enrollment: 46 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


New York

Roswell Park Cancer Institute

Buffalo, NY

Open and Accepting


West Penn Hospital (Allegheny Health Network)

Pittsburgh, PA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message